KR
Krystal Biotech
KRYS·NASDAQPittsburgh PAFounded 2016400 employees
Mid CapbiotechPublicDermatologyRare DiseaseRespiratory
Platform: HSV Gene Ther
Market Cap
$6B
All Drugs
4
Clinical Trials
6
Failed / Terminated
2
FDA Approved
0
Stock Price & Catalysts (KRYS)
Loading KRYS stock data...
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Nidaratamab | KRY-8758 | Preclinical | 2 | RET | Hemophilia A | ||
| Semainavolisib | KRY-4942 | Phase 2 | 2 | B7-H3 | LGS | ||
| Terarasimod | KRY-3684 | Phase 1/2 | 1 | PI3Kα | Cervical Ca | ||
| Liratinib | KRY-9571 | NDA/BLA | 1 | TIM-3 | Meso |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (6)